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Background: The introduction of highly active antiretroviral therapy (HAART) has enabled the dramatic
reduction in viral replication and the partial restoration of host immune function, albeit at the expense
of drug toxicity. Strategies to enhance HIV-speciﬁc immunity are required in order to limit ART exposure.
Therapeutic vaccination is a promising new approach to enhance immunogenicity and anti-viral activity
in people infected with HIV.
Purpose: Efﬁcient clinical trial designs are required to optimize therapeutic HIV vaccination strategies.
Herein, we describe unique design features and investigational procedures that were applied to a
prime-boost therapeutic vaccine trial (CTN 173) to enhance HIV immunity.
Methods: CTN 173 was a multicentre, randomized, 3-arm, double-blind placebo controlled trial to eval-
uate anti-viral activity of therapeutic vaccination with ALVAC ± Remune in chronically infected individ-
uals on HAART. CTN 173 was developed with the speciﬁc aim to better characterize patient factors and
immunologic parameters associated with vaccine response. This paper discusses the relevance of choice
of primary endpoint and statistical approach used in this trial, in relation to vaccine response, patient
safety and the identiﬁcation of optimal target populations for future vaccine trials.
Results: Time to event surrogate endpoints of viral response and frequent immunologic monitoring allow
for a better characterization of immunologic correlates of vaccine response.
Limitations: The clinical implications of delayed viral rebound associated with therapeutic vaccination
with ALVAC + Remune are not yet known and will need to be evaluated on long-term follow-up.
Conclusions: Randomized controlled trials such as CTN 173, with well-deﬁned surrogate endpoints and
frequent immunologic and virologic monitoring, are necessary to streamline the approach to effective
vaccine discovery and to ensure patient safety.
 2012 Elsevier Lt .d Open access under CC BY-NC-ND license.1. Background Re-exposure to the HIV antigen using structured treatmentOn-going HIV replication following initial infection leads to pro-
gressive immune deﬁciency. Highly active antiretroviral therapy
(HAART) can effectively maintain HIV RNA at undetectable levels
(<50 copies/ml) and allows for the preservation of general and
HIV-speciﬁc immunity. HIV-infected individuals on HAART may
therefore be amenable to strategies capable of further enhancing
immune function. Novel approaches to strengthen immune re-
sponses to HIV may allow for limited ART exposure.us Diseases, Ottawa Hospital
Canada K1H 8L6. Tel.: +1 613
Y-NC-ND license.interruptions (STI), often referred to as autoimmunization, is a
strategy that has been to tested to boost anti-HIV immunity
[1,2]. Despite the potential beneﬁts of this approach in limiting
the time on therapy and the associated cost and toxicity of
treatment, the evidence to support the immunologic beneﬁt of
STI remains equivocal [3,4]. Further, the absence of durable
virologic control of HIV after ART discontinuation combined with
the associated declines in CD4 count and worse clinical outcomes,
has prevented this strategy from being recommended in the rou-
tine management of patients with HIV infection [5,6]. Nonetheless,
in the context of the controlled clinical setting, analytic treatment
interruption (ATI) continues to be acceptable in the testing of
therapeutic HIV vaccines [5].
Therapeutic immunization strategies designed to stimulate
anti-viral activity by enhancing HIV-speciﬁc immune response
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ing characteristics of successful preventative vaccines, putative
therapeutic HIV vaccines have been chosen based on their ability
to enhance cytotoxic T lymphocyte (CTL) responses and CD4 T cell
help. Most recently, vaccination strategies ofmultiple vaccines and/
or immunemodulating agents have been undertaken in order to en-
hance and expand the breadth of the HIV-speciﬁc immune response
[9–12] and because of the limited clinical efﬁcacy of single agent
trials.
Efﬁcient clinical trial designs are required to optimize therapeu-
tic HIV vaccine strategies, as optimal target populations and immu-
nologic correlates of vaccine response remain poorly deﬁned. CTN
173 was a randomized double-blinded placebo controlled trial of
ALVAC (a modiﬁed recombinant canarypox virus) and Remune
(whole killed HIV) in chronically HIV-infected individuals on ART.
This study was undertaken to better characterize clinical features
of the host and immunologic responses associated with control
of HIV following ATI of HAART, using well deﬁned endpoints, fre-
quent immunologic monitoring and stringent eligibility criteria.
Herein, following a brief study overview, we explore the unique
design features of CTN 173 that enhanced the design efﬁciency of
this therapeutic HIV vaccine trial.2. Methods
2.1. Design overview
CTN 173 was designed as a multicentre, randomized, double-
blind placebo controlled trial to evaluate anti-viral activity of ther-
apeutic vaccination with ALVAC ± Remune in chronically infected
individuals on HAART. This 3-arm study (1:1:1) was designed to
evaluate the individual and additive effect of complementary vac-
cines on HIV-speciﬁc immunity, with the expectation that com-
bined vaccination (ALVAC + Remune) would induce the greatest
treatment effect. Brieﬂy, Remune™ is a chemically and physically
inactivated gp120-depleted HIV-1 adjuvanted with Incomplete
Freund’s Adjuvant (IFA) that has been shown to enhance cellular
immune responses [13,14] and has a good safety proﬁle [15–17].
In CTN 173, Remune™ or its placebo, IFA, were administered
(1 ml i.m.) at weeks 0, 12 and 20. ALVAC (vCP1452) is a preparation
of a modiﬁed recombinant canarypox virus, expressing the gene
products of the HIV-1 env and gag genes and a synthetic polypep-
tide encompassing the known human CTL epitopes from the nef
and pol gene products, which can be safely be administered to
HIV-infected adults to target CTL responses [11,18,19]. In CTN
173, ALVAC or its placebo (saline) was administered (1 ml i.m.)
at weeks 8, 12, 16 and 20.
HIV-infected individuals (aged >18 years) were able to partici-
pate in CTN 173 if they were receiving at least three antiretrovirals
and had a plasma HIV RNA level <50 copies/ml for a minimum of
2 years. CD4 eligibility criteria at baseline consisted of absolute
CD4 count >500 cells/ll, CD4 to CD8 ratio >0.5 and CD4+ T cell na-
dir (lowest CD4 count ever) >250 cells/ll. Study participants re-
ceived vaccination or placebo for 20 weeks, while continuing on
ART. At week 24, ART was discontinued and study participants
were monitored for viral rebound and CD4 decline, which precipi-
tated ART re-initiation. Protocol deﬁned criteria for re-initiating
ART are presented in Fig. 1. The primary endpoint was time to
detectable levels of HIV RNA (>50 copies/ml).
To characterize immunologic responses associated with control
of HIV study participants underwent frequent virologic monitoring
and immunologic investigations during vaccination and following
ART withdrawal. Speciﬁcally, CD4 counts and viral load testing
began 4 weeks before the ﬁrst vaccination and continued every
4 weeks until week 24 in all subjects. At the time of ATI, viral loadmeasurements were scheduled twice a week for 4 weeks (weeks
25–28 inclusive) and then weekly during weeks 29–36, or until
the patient reached one of the conditions to restart ART. Viral loads
were then evaluated monthly after week 36 for study participants
who continued off ART. CD4 counts in all patients were carried out
every 4 weeks from week 24 to 48. Finally, immunologic investiga-
tions were performed in all patients at screening and 4 weeks be-
fore vaccination as well as at weeks 0, 12 and 20 (during
vaccination) and weeks 24, 28, 32, 36 and 48, after ART was discon-
tinued, and included evaluations of HIV-speciﬁc CTL and T helper
cell responses. All study participants were monitored during ATI
until week 48, at which point study participants with detectable
HIV RNA were to re-initiated ART (Fig. 1). The primary analysis
of virologic, clinical and immunological endpoints was conducted
upon the completion of 48 weeks of follow-up in all study partici-
pants. Additional analyses were also proposed after 3 years of fol-
low up, to evaluate the potential lasting clinical impact of early
vaccine response. This study was conducted in accordance with
the ethical standards on human experimentation of the Declara-
tion of Helsinki and was approved by the local research ethics
board at each participating centre.3. Design efﬁciency in therapeutic HIV vaccine trials
To streamline the approach to vaccine discovery, trials of
putative HIV therapeutic vaccines must be designed to not only
accurately quantify vaccine immunogenicity and anti-viral activity
but must also help deﬁne optimal target populations and identify
immunologic correlates of vaccine responsiveness, all the while
preserving patient safety. CTN 173 was novel in its application of
design features to speciﬁcally address these issues. A review of
design features that will optimize and advance therapeutic HIV
vaccine discovery is presented below, using CTN 173 as a case in
point.
3.1. Randomized clinical trial
Therapeutic vaccine trials have been plagued with many of the
well-known biases inherent in single arm observational studies.
To date, only a limited number of randomized therapeutic HIV
vaccine trials have been carried out [20–26]. Despite the added
complexity of randomized controlled trials, their use in the study
of vaccine response provides a unique opportunity to accurately
quantify treatment effect (without the confounding effects intro-
duced by the use of historical controls) and to identify host
immunologic responses associated with the control of viral repli-
cation – both critical to effective vaccine development. Using a
placebo-controlled randomized study design, CTN 173 was able
to accurately quantify the delay of viral rebound associated with
vaccination and identify vaccine-induced immunologic responses
associated with improved control of HIV replication on ART with-
drawal [26]. Through standard blinding procedures, CTN 173 also
minimized the ascertainment and selection biases of previous
open-label trials.
3.2. Choice of primary endpoint
The choice of primary endpoint is critical to the testing of new
vaccines. Although a demonstration of clinical beneﬁt is the
ultimate goal of therapeutic vaccination, predictive markers of
HIV disease progression are required as surrogate endpoints in
vaccine trials to streamline the approach to effective vaccine
discovery. Plasma viral load has been proposed as a viable primary
endpoint in therapeutic vaccine trials [27] based on its strong
association with disease progression [28]. Steady state viral load
Fig. 1. CTN 173 vaccination and treatment schedule.
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endpoints of choice in therapeutic vaccine trials to date, in part
due to the intrinsic difﬁculty of accurately determining the timing
of viral rebound. The frequent viral and immunologic monitoring
following ATI in CTN 173 overcame this difﬁculty and allowed
for a time to event analysis of viral rebound, which represents a
more efﬁcient study design possibly allowing for host characteris-
tics of vaccine response to be better deﬁned.3.2.1. Sample size estimation
The primary endpoint of CTN 173 was time to plasma HIV-RNA
viral rebound to detectable levels (>50 copies/ml) following ART
discontinuation. Unlike viral load set point, which demonstrates
a high degree of inter-patient variability [29], time to viral rebound
(>50 copies/ml) has been well characterized [4]. In non-vaccinated
subjects undergoing STI, viral rebound occurs a mean of 10 days
after discontinuing therapy [4,30,31]. As such, the choice of time
to viral rebound as the primary endpoint in CTN 173 enabled accu-
rate power and sample size calculations, a notable improvementover previous therapeutic trials that compared mean viral set point
or viral load at a pre-speciﬁed point in time [7,32]. CTN 173 was
designed to have 80% power to detect a delay in viral rebound of
10 days with an alpha of 0.05 and recruited a total of 60 partici-
pants to the study, of which 57 completed vaccination and inter-
rupted ART [26].3.2.2. Time to event analyses
The use of time to event analysis in CTN 173 was a notable dif-
ference from other therapeutic vaccine trials, which have simply
compared steady state viral load or viral load at 12 weeks between
treatment arms, following ATI [7,32]. The comparison of viral
set-point as the primary measure of vaccine response in previous
therapeutic vaccine trials not only presents difﬁculty in the estima-
tion of sample size requirements, for the above mentioned reasons,
but also makes inefﬁcient use of virologic and immunologic
response data and may allow important early differences in
vaccine response to go undetected. In the case of CTN 173, the
median time to viral rebound (>50 copies/ml) following ATI was
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cine arm (ALVAC + Remune), as compared to the placebo arm [26].
Viral load by treatment arm is presented in Fig. 2 for the early
phase of the ATI, after which point the viral load stabilized and
was similar across treatment arms [26]. While the delay in viral re-
bound was not found to be statistically signiﬁcant given the small
sample size, the time-to-event approach used to evaluate vaccine
response may advance vaccine development, by harnessing the
early control of viral replication observed. The clinical signiﬁcance
of the early vaccine-induced control of viral replication observed in
CTN 173 is currently under investigation.
3.3. Characterization of immunologic characteristics of vaccine
response
A comprehensive set of exploratory immunologic investiga-
tions was also integrated into the overall study design of CTN
173, with the aim to better characterize immunologic correlates
of vaccine response. Importantly, as a result of the frequent mon-
itoring during CTN 173, IFN-gamma and IL-2 responses were
found to be associated with time to viral rebound, which would
have gone undetected under standard viral load set-point com-
parisons [26]. The short-lived nature of this association is cur-
rently under investigation at our laboratory, as we attempt to
understand immunologic responses associated with the early
viral control.
3.4. Patient safety
Analytic treatment interruptions are commonly employed in
therapeutic HIV vaccine trials to evaluate host control following
vaccination. The continued use of this strategy in such trials is
predicated on its safety. Vaccine trial designs must aim to contin-
ually reﬁne eligibility criteria and identify host factors that make
STI and ATI safe. With this aim, CTN 173 integrated both disease
history and immunologic evaluations into the overall study design
and considered their relationship with early viral rebound upon
ART discontinuation.
3.4.1. Inclusion criteria
The extent of immunologic damage, as reﬂected in the CD4
nadir, is recognized as an important predictor of future diseaseFig. 2. Viral rebound by treatment arm. Adapted from Angel JB et al. [26].progression. CD4 nadir was included as an eligibility criterion
and as part of the baseline evaluation in CTN 173 to better charac-
terize the impact of disease history on response to therapeutic vac-
cination. Of interest, despite the known impact of CD4 nadir on
viral load rebound during STI [33,34], eligibility criteria for the
majority of therapeutic vaccination trials involving individuals on
suppressive ART have typically only focused on the CD4 count at
the time of study enrolment. Speciﬁc to CTN 173, CD4 nadir
>250 cells/ll was an eligibility criterion, to exclude subjects from
the trial in whom extensive general and HIV-speciﬁc immunity
had occurred. The safety of study participants will be further en-
hanced to the extent that parameters of disease history known to
negatively impact response following STI are included in the eligi-
bility criteria for vaccination strategies.3.4.2. Frequent virologic and immunologic assessments
Unique to CTN 173, a comprehensive set of exploratory immu-
nologic investigations was also integrated into the overall study
design, with the aim to better deﬁne immunologic correlates of
vaccine response. By enabling a more comprehensive character-
ization of the pattern of viral rebound in the context of vaccine-
induced changes of immunologic parameters, this study was
designed to not only deﬁne target populations and immunologic
responses that would produce optimal vaccine responses but also
to identify immunologic parameters predictive of early increases
in viral load following ART withdrawal. In the case of CTN 173,
proliferative responses were not found to be associated with time
to viral rebound, however vaccine induced IFN-gamma and IL-2
responses were both necessary for vaccine response – suggesting
that in the absence of these immunologic responses, ATI may not
be advisable. Importantly, the vaccines used in CTN 173 were
well tolerated, with a limited number of adverse events reported
that were not found to differ between treatment groups [26]. The
safety of study participants will be promoted to the extent that
design features, such as reﬁned eligibility criteria and frequent
immunologic assessments, are included in therapeutic HIV vac-
cine trials.4. Discussion
Although HAART has signiﬁcantly improved the survival of peo-
ple infected with HIV, the toxicity, cost and potential complexity of
the regimens make drug adherence, and consequently drug
resistance, an on-going concern. Immune modulating strategies
to enhance HIV-speciﬁc immunity and control HIV replication are
therefore necessary to limit drug exposure.
In the presence of uncontrolled viremia, strategies to strengthen
the immune system have proven unsuccessful [35,36]. The preser-
vation of immune responsiveness as a result of viral suppression
with the use of HAART has renewed interest in therapeutic
vaccination strategies to control HIV replication. Therapeutic
vaccination in the setting of suppressed viral replication with
ART represents an important opportunity to delay disease progres-
sion and improve the quality of life of people living with HIV.
Herein, we review some of the important features of CTN 173 that
enhanced the design efﬁciency of this randomized controlled
therapeutic HIV vaccine trial which contributed to the reﬁnement
of target populations and host immune responses most likely to
beneﬁt from therapeutic vaccination strategies.
While endpoints based on HIV RNA levels (i.e. time to viral load
rebound, viral load set point) are now commonly employed in HIV
vaccine trials, the clinical relevance of study results based on such
endpoints will ultimately be required. The use of early virologic
predictors of disease progression in therapeutic vaccine studies
will, however, reduce the likelihood of premature trial closure of
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have hindered earlier therapeutic trials. While the 3-year follow
up-results of CTN 173 are pending, the preliminary results point
to the added utility of time to viral rebound as a primary endpoint
and highlight the importance of frequent virologic and immuno-
logic monitoring to reﬁning optimal target populations and desir-
able immunologic host responses. Continued reﬁnements to the
eligibility criteria and a more accurate understanding of immuno-
logic correlates of vaccine response and disease history that may
impact vaccine immunogenicity, anti-viral activity and patient
safety are required. Therapeutic HIV vaccine trialsmust be designed
to optimize efﬁciency. Well designed randomized placebo con-
trolled trials, like CTN 173, are necessary in the testing of novel
immune boosting strategies enabled by HAART. Continued studies
of alternatives to ART are required to limit toxicity and reduce the
ﬁnancial burden of treatment of a disease infecting 33 million
people worldwide.
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